FIELD: biotechnology.
SUBSTANCE: invention relates to production of trispecific binding proteins and can be used in medicine in cancer therapy. Disclosed is a trispecific binding protein CD38/CD28xCD3, comprising a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site which binds a third polypeptide, such as a human tumour target protein HER2.
EFFECT: invention provides activation of T-cells, by means of which potential of immune cells is induced with respect to destruction of nearby tumour cells.
44 cl, 18 dwg, 12 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
